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The mechanisms that protect eukaryotic DNA during
the cumbersome task of replication depend on the
precise coordination of several post-translational
modification (PTM)-based signaling networks. Phos-
phorylation is a well-known regulator of the replica-
tion stress response, and recently an essential role
for SUMOs (small ubiquitin-like modifiers) has also
been established. Here, we investigate the global
interplay between phosphorylation and SUMOylation
in response to replication stress. Using SUMO and
phosphoproteomic technologies, we identify thou-
sands of regulated modification sites. We find co-
regulation of central DNA damage and replication
stress responders, of which the ATR-activating
factor TOPBP1 is the most highly regulated. Using
pharmacological inhibition of the DNA damage
response kinases ATR and ATM, we find that these
factors regulate global protein SUMOylation in the
protein networks that protect DNA upon replication
stress and fork breakage, pointing to integration be-
tween phosphorylation and SUMOylation in the
cellular systems that protect DNA integrity.
INTRODUCTION
DNA replication is a tremendously challenging, time-consuming,
and vital task for eukaryotic organisms. The maintenance of
genomic integrity during this process is challenged by endoge-
nous and exogenous factors that cause replication forks to
slow and stall, and, in extreme cases, this leads to DNAbreakage
(Halazonetis et al., 2008). Cells are equipped with a complex
DNA damage response (DDR) consisting of protein networks
that enable them to cope with replication stress (RS), and a
malfunction in these systems can result in genomic instability
and oncogenesis (Jackson and Bartek, 2009). These protective546 Cell Reports 21, 546–558, October 10, 2017 ª 2017 The Authors
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coordination of DDR components, which is achieved by dynamic
and specific post-translational modifications (PTMs) (Polo and
Jackson, 2011). In particular, protein phosphorylation is a well-
established driver of the RS response, with the ATR (ataxia telan-
giectasia and Rad3-related protein) kinase functioning as the
key initiator and orchestrator (Lo´pez-Contreras and Fernan-
dez-Capetillo, 2010; Shiloh, 2001). Depletion of this central
kinase leads to replication fork breakage and genomic instability,
instigating a phosphorylation response mounted by the ATM
(ataxia telangiectasia mutated) kinase, which mediates repair
and checkpoint activation upon double-strand breaks (DSBs)
(Murga et al., 2009; Smith et al., 2010). ATM and ATR belong
to the same atypical serine/threonine kinase family (the phos-
phatidyl inositol 30 kinase-related kinases [PIKK]-related kinases)
with similar substrate sequence specificity (Kim et al., 2009), but
they have unique triggers. Although ATR responds to the
accumulation of single-stranded DNA (ssDNA) and regulates
replication, ATM is the key mediator of the cellular response to
DSBs. DNA-dependent protein kinase (DNA-PK) is the third
member of this kinase family; however, its functions are confined
to local repair processes (Meek et al., 2008).
Phosphorylation, however, must act in concert with other
PTMs, such as ubiquitylation, to elicit efficient responses to
genotoxic insults (Ulrich and Walden, 2010). The functions of
PTMs in the DNA damage and RS responses have therefore
been subject of intense investigations, individually (Beli et al.,
2012; Bennetzen et al., 2009; Danielsen et al., 2011; Jungmichel
et al., 2013) and in concert (Gibbs-Seymour et al., 2015; Gonza´-
lez-Prieto et al., 2015; Hunter, 2007). More recently, studies have
revealed the significance of protein SUMOylation in the DDR,
and deregulation of the small ubiquitin like modifier (SUMO)
system has been shown to confer genomic instability (Bergink
and Jentsch, 2009; Bursomanno et al., 2015; Jackson and
Durocher, 2013; Xiao et al., 2015). Using various RS-inducing
agents, these studies have shown that the SUMOylation status
of a number of proteins is modulated when DNA replication is
perturbed (Garcı´a-Rodrı´guez et al., 2016). Furthermore, it has
been demonstrated that phosphorylation and SUMOylation.
commons.org/licenses/by/4.0/).
intersect at various levels (Gareau and Lima, 2010). A phosphor-
ylation-dependent SUMO modification (PDSM) motif has been
suggested to prime SUMOylation (Hietakangas et al., 2006)
by enhancing the binding of the SUMO E2 enzyme UBC9
(Mohideen et al., 2009), and phosphorylation was also found
to regulate the function of SUMO-interacting motifs (SIMs)
(Stehmeier and Muller, 2009). However, a potential global
coordination of the SUMOylation response and the well-known
phosphorylation response to RS remains unexplored.
Quantitative mass spectrometry (MS)-based proteomics and
developments in enrichment methodologies have seen tremen-
dous developments in recent years (Hendriks and Vertegaal,
2016). State-of-the-art MS technologies allow the identification
of thousands of SUMOylation sites (Hendriks et al., 2017;
Lamoliatte et al., 2014, 2017; Schimmel et al., 2014; Tammsalu
et al., 2014) and tens of thousands of phosphorylation sites
from cellular systems (Francavilla et al., 2017; Mertins et al.,
2016; Olsen et al., 2010). In this study, we utilized complemen-
tary proteomics strategies to identify the interplay between the
global SUMOylation and phosphorylation responses to replica-
tion stressors. We identified regulation of thousands of phos-
phorylation sites and hundreds of SUMOylation sites in response
to treatment with the DNA inter-strand crosslinking (ICL) agent
mitomycin C (MMC) and hydroxyurea (HU), with a number
of proteins co-regulated by both PTMs. Our investigations
revealed that the well-established apical responders to RS and
RS-induced DSBs, ATR and ATM, both modulate protein
SUMOylation at various stages of the RS response. Our findings
not only identify an intersection between phosphorylation
and SUMOylation in the RS response but also reveal further
levels of signaling regulation in this response by the two most
prominent kinases of the DNA damage and RS responses.
RESULTS
Global SUMOylation Changes upon MMC Treatment
To investigate the interplay between the SUMOylation and
phosphorylation responses to RS, we treated U-2-OS osteosar-
coma cells with MMC (Figure 1A). MMC, a widely used chemo-
therapeutic agent in the treatment of various cancers, induces
ICLs, thereby impeding normal replication fork progression and
causing RS. To study the effects of MMCduring DNA replication,
cells were synchronized at the G1/S checkpoint by 24 hr of
thymidine blocking and were thereafter released into S phase
with or without MMC for 8 hr (Figure 1B; Figure S1A). After
an 8 hr release into MMC, western blotting confirmed increased
phosphorylation of checkpoint kinases, CHK1 at S435 and
CHK2 at T68, as well as increased levels of phosphorylation of
S140 on histone H2A.X (gH2AX) (Figure S1B). These phosphor-
ylation sites are known targets of ATR and ATM, indicating
that our experimental conditions generate RS (ATR activation)
and DSBs (ATM activation).
For MS-based global analysis of SUMOylation, we used
two previously described SUMO enrichment approaches to
quantify changes in protein SUMOylation and SUMO acceptor
sites (Hendriks et al., 2014; Schimmel et al., 2014) on a global
scale (Figure 1B). SUMOylated proteins were identified and
quantified by immunoprecipitation (IP) of SUMO2-conjugatedproteins from U-2-OS cells stably expressing FLAG-SUMO2-
Q87R (Figure 1C; Figure S1C). The Q87R mutation allows for
identification of SUMO sites after tryptic digestion because of
the resulting remnant (Schimmel et al., 2014). To confidently
distinguish SUMOylated from non-SUMOylated proteins, con-
trol IPs were also performed from the parental U-2-OS cell line
because non-SUMOylated proteins would be underrepresented
in these compared with FLAG-SUMO2-Q87R-expressing cells
(Figure 1B). Complementarily, we mapped SUMOylation
acceptor sites by enrichment of SUMOylated peptides from
His10-tagged SUMO2-K0-Q87R-expressing U-2-OS cells (Fig-
ure 1B; Xiao et al., 2015). Tryptic peptides from all enriched
samples were analyzed by nano-scale liquid chromatography-
tandemMS (LC-MS/MS) on aQ-Exactive high-frequency (HF) in-
strument (Kelstrup et al., 2014). We used stable isotope labeling
by amino acids in cell culture (SILAC) (Ong et al., 2002) for accu-
rate MS-based quantification, and differentially labeled SILAC
cells showed comparable cell cycle distributions upon synchro-
nization (Figure S1A). The SUMO2 expression levels in the two
stable cell lines were 3- to 4-fold higher than in the parental cells,
as observed byMS full scans from proteomemeasurements and
by western blotting (Figures S1D and S1E).
All raw LC-MS/MS files were processed and analyzed
together using the MaxQuant software suite (http://www.
coxdocs.org/doku.php?id=maxquant:start) with a 1% false
discovery rate at the peptide, site, and protein levels (Cox and
Mann, 2008). From this analysis, we confidently identified
3,453 proteins (Table S1). Ratios from proteome measurements
of these conditions revealed that the protein abundances in
the MMC-treated FLAG-SUMO2-Q87R cells were largely un-
changed compared with the equivalently treated parental cells.
We therefore reasoned that we could determine the proteins
significantly SUMOylated in FLAG-SUMO2-Q87R cells using
ratio cutoffs of 2 SDs from the mean (95th percentile) of this ratio
distribution (Figure S1F). This analysis resulted in a cutoff of
1.7-fold change, by which 702 proteins were deemed to be
SUMOylated (Figure 1D; Table S1). Using the same strategy
for the MMC-treated and untreated FLAG-SUMO2-Q87R cells,
a resulting ratio cutoff of 1.5 resulted in 187 proteins having
significantly increased SUMOylation upon treatment with MMC
(Figure 1D; Figure S1G; Table S1). Additionally, we mapped
311 unique SUMO acceptor sites (Figure 1E). Sequence motif
analysis of these showed a strong preference for a glutamate
two residues downstream of the modified lysine (Figure 1E),
conforming to the previously described SUMOylation consensus
motif (JKXE) (Sampson et al., 2001). By separately analyzing
SUMOylated peptides with or without this motif, we found that,
indeed, the known SUMO consensus motif is predominant,
with the inverted SUMO motif the secondmost overrepresented
(Figure 1E).
To determine the cellular compartments and biological
processes in which the SUMOylated proteins are involved, we
performed a gene ontology (GO) enrichment analysis. In agree-
ment with previous studies, we found that the majority of
SUMOylation occurs on nuclear proteins that are involved in
transcription (Figure S1H; Flotho and Melchior, 2013). Further,
among the proteins withMMC-regulated SUMOylation, we iden-
tified 24 transcription factors for which 24 target genes wereCell Reports 21, 546–558, October 10, 2017 547
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found to be co-regulated by at least two of these. Interestingly,
these target genes were highly enriched in proteins involved in
apoptosis and cancer development (Table S1). GO analysis
of the 187 proteins with increased SUMOylation after MMC
treatment also revealed this trend, and, furthermore, these pro-
teins are involved in histone ubiquitylation and DNA repair
(Figure 1F).
Many of the identified proteins known to function in DNA repair
clustered together in a functional network based on search tool
for recurring instances of neighboring genes (STRING) database
analysis (Szklarczyk et al., 2015). Fanconi anemia factors,
BRCA1 (breast cancer type 1 susceptibility protein), and
TOPBP1 (DNA topoisomerase 2-binding protein 1) were among
the regulated SUMOylated proteins after MMC treatment (Fig-
ure 1G). These proteins are well-known to play important roles
in response to ICL-induced RS and DNA damage. The regulation
of SUMOylation levels on these proteins upon MMC treatment
indicates that this modification may modulate their function in
this response.
Global Phosphorylation Changes upon MMC Treatment
To study the potential interplay between the SUMOylation and
phosphorylation responses to MMC, we used a streamlined
quantitative phosphoproteomics workflow (Batth et al., 2014)
to enrich phospho-peptides from FLAG-SUMO2-Q87R U-2OS
cells synchronized and treated with MMC in the same manner
as for SUMOylation mapping. Tryptic digests of whole-cell
lysates were separated by offline high-pH reverse-phase frac-
tionation, and phospho-peptides were enriched with TiO2 beads
prior to LC-MS/MS (Figure S2A). We quantified 20,900 high-con-
fidence phosphorylated sites, of which 650 were induced (SILAC
ratio above 1.5) after 8 hr of MMC treatment (Figure 2A; Table
S2). Proteins with induced phosphorylation were primarily
nuclear and involved in DNA repair, as determined by GO anal-
ysis, similar to our findings for SUMOylated proteins that were
induced by MMC treatment (Figure 2B; Figure S2B).
We performed sequence motif analysis of the 650 upregulated
phosphorylation sites to identify protein kinases that were acti-
vated in the response toMMC treatment. A strong overrepresen-
tation of glutamine (Q) at the position directly C-terminal to the
phosphorylation sites (P+1) indicated activation of the ATM
andATR kinases, both of which are known to preferentially phos-
phorylate substrates on serine/threonine residues that are
followed by a glutamine (S/T-Q) (Figure 2C). Indeed, we found
that 170 (26%) of the phosphorylation sites upregulated by
MMC treatment confer to the S/T-Qmotif. Moreover, MS spectra
show a clear induction of ATM and ATR target phosphorylationFigure 1. Proteomics Analysis of SUMOylation Changes upon MMC Tr
(A) Schematic of the aim to study a potential interplay between phosphorylation
(B) Experimental design for proteomics analysis of SUMOylated proteins fr
SUMOylated proteins and peptides, respectively.
(C) Western blot analysis of SUMO-enriched proteins from SILAC-labeled U-2-O
treated as in (A).
(D) Results of the proteomics analysis.
(E) Motif analysis of SUMOylation acceptor sites.
(F) Enrichment analysis of GO cellular compartments (GOCC) and biological pro
(G) Functional network analysis of proteins from the GOBP terms enriched in (F)
See also Figure S1 and Table S1.sites on ATM itself and CHK1, respectively (Figure 2D).
Conversely, phosphorylation sites on proteins from other
signaling pathways, as exemplified by ERK1, remained largely
unperturbed (Figure 2D). Functional network analysis of proteins
with increased phosphorylation reveals two highly inter-
connected clusters of phosphoproteins involved in the DDR,
DNA replication, and cell cycle (Figure 2E). A number of these
proteins were also found to have increased SUMOylation, indi-
cating that phosphorylation and SUMOylation are modulating
proteins in the same pathways in the RS response to MMC
treatment.
Central DDR Proteins Are Highly Phosphorylated and
SUMOylated in Response to MMC
To elaborate on this hypothesis and uncover a potential interplay
between the SUMOylation and phosphorylation responses
to MMC, we integrated our large-scale proteomics datasets of
the twomodifications. First we evaluated the datasets for poten-
tial biases arising from the MS strategies used for enrichment
and detection of proteins with these modifications. The distribu-
tion of the relative protein copy numbers (intensity-based
absolute quantification [iBAQ] values) from the proteome, the
phosphorylated proteins, and the SUMOylated proteins in these
datasets revealed that all three groups of proteins had similar
distribution patterns with no apparent abundance biases (Fig-
ure S3A). We then assessed the overlap between the datasets
and found that 540 proteins harbored at least one SUMOylation
and phosphorylation event (Figure 3A). This comprises two-
thirds of the SUMOylated proteins we identified, corresponding
to the proportion of the total proteome that is reported to be
phosphorylated at any given time (Olsen et al., 2010). Although
only 17 of these proteins were found to have upregulation of
both modifications upon MMC treatment, this subset included
UIMC1 (BRCA1-A complex subunit RAP80), BRCA1, BARD1
(BRCA1-associated RING domain protein 1), and TOPBP1,
which are proteins with well-established key functions in the
DDR (Figures 3A and 3B; Table S3). We therefore find that
quantitative analysis of proteins co-regulated by both PTMs is
a powerful means to determine and prioritize key players in
cellular signaling networks.
To elaborate on the mechanism of regulation of these two
PTMs in RS, we further investigated the roles of most prominent
DDR- and RS-activated kinases, ATR and ATM, in modulating
RS-induced SUMOylation (Smith et al., 2010). These kinases
are well-known initiators and key modulators of the global
phosphorylation and ubiquitylation responses to DNA damage
and RS (Shiloh, 2001). Indeed, ATR is activated upon 8 hr ofeatment
and SUMOylation in MMC-induced RS.
om FLAG-SUMO2- and His10-SUMO2-expressing U-2-OS cells to enrich
S cells stably transfected with FLAG-SUMO2. Cells were synchronized and
cesses (GOBP) of MMC-regulated SUMOylated proteins using InnateDB.
.
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Figure 2. Phosphoproteomics Analysis of MMC-Treated cells
(A) Overview of the number of phosphorylated peptides and proteins from phosphoproteomics analyses of cells treated as shown in Figure S2A.
(B) GOCC and GOBP analysis of proteins with regulated phosphorylation sites after MMC treatment using InnateDB.
(C) Motif enrichment analysis of 360 MMC-dependent phosphorylation sites, done with IceLogo.
(D) Full MS spectra of phosphorylated peptides from ATM, CHK1, and ERK1.
(E) Two highly interconnected molecular complex detection (MCODE) clusters from functional network analyses of all proteins with regulated phosphorylation
sites. MCODE was set to determine clusters with the ‘‘Haircut’’ approach, a minimum node score cutoff of 0.2; K-core was set to 2, and max depth to 100.
See also Figure S2 and Table S2.MMC treatment after thymidine release, as observed by
increased phosphorylation of its direct target CHK1 on S345,
which can be further attenuated with an ATR inhibitor (ATRi)
(Figure S3B). Interestingly, TOPBP1, an important co-activator
of ATR, was the highest co-modified protein upon MMC treat-
ment (Figure 3B). By SUMO enrichment from both FLAG-
SUMO2-Q87R and His10-tagged SUMO2-K0-Q87R cells, we
were able to confirm that, indeed, TOPBP1 SUMOylation is
increased over time with MMC treatment (Figure 3C). Because
the His10-based pull-down procedures involved lysis and
enrichment under harsh denaturing conditions, these findings
confidently demonstrate that TOPBP1 is indeed differentially550 Cell Reports 21, 546–558, October 10, 2017SUMOylated by RS and that the observed changes are not
due to TOPBP1 interactions with other SUMO-regulated target
proteins. Interestingly, TOPBP1 SUMOylation was further
induced upon co-treatment of MMC with ATRi, also at earlier
time points (Figure 3D). Although TOPBP1 SUMOylation is
increased upon treatment with MMC or ATRi only, the combina-
tion of the two is required for massive hyper-SUMOylation
(Figure 3D). ATM is also activated under these conditions, as
indicated by increased CHK2 and H2A.X phosphorylation (Fig-
ure 3D; Figure S3B), and, interestingly, hyper-SUMOylation of
TOPBP1 upon MMC and ATRi co-treatment was significantly
reduced by ATM inhibition (Figure 3D). Thus, in contrast to
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Figure 3. Integrated Analyses of SUMOylation and Phosphorylation Datasets
(A) Overlap of all identified and regulated SUMOylation and phosphorylation substrates.
(B) Functional network analysis of the 17 proteins with regulated phosphorylation and SUMOylation.
(C) Validation of TOPBP1- and BRCA1-regulated SUMOylation in FLAG-SUMO2 U-2-OS cells blocked for 24 hr with thymidine and then treated for 8 hr with or
without MMC. FLAG-IP, FLAG-based immunoprecipitation; His-PD, His-based pull-down.
(D) Western blot analysis of TOPBP1 SUMOylation upon treatment for 8 hr with MMC with and without ATR inhibitor (ATRi, ATR-45) and ATMi (ATMi, KU55933).
See also Figure S3 and Table S3.well-known phospho-induced SUMOylation, it appears that
modulation of phosphorylation networks can also reduce
SUMOylation in this context, expanding the repertoire of phos-
pho-SUMO crosstalk.
These observations are in accordance with the induction of
DNA DSBs and ATM activation that arises upon RS in combina-
tion with checkpoint inhibition (Toledo et al., 2013; Figure 4A). To
validate our observation that central DDR kinases modulate
hyper-SUMOylation of TOPBP1 upon MMC treatment and
determine whether such regulation occurs on other proteins,
we performed an additional label-free quantitative proteomics
screen. Here we analyzed enriched SUMOylated proteins from
MMC-treated cells in combination with the ATM inhibitor
(ATMi) and ATRi (Figure 4B; Figure S4A; Table S4).We confirmed
that TOPBP1 is hyper-SUMOylated by co-treatment with MMC
and ATRi and that this was attenuated upon addition of ATMi
(Figures 4C and 4D). Remarkably, ATR itself and its constitutive
interactor ATR interacting protein (ATRIP), which localizes ATRto TOPBP1 for activation, both displayed the same hyper-
SUMOylation pattern as TOPBP1 (Figures 4C and 4D). Although
SUMOylation of ATRIP and ATR has previously been reported
in response to UV and HU treatments (Wu et al., 2014), we
found that hyper-SUMOylation of ATR, ATRIP, TOPBP1, and
XRCC6 (X-ray repair cross-complementing protein 6) arises
upon RS in combination with checkpoint inhibition. Importantly,
STRING-based functional network analysis of SUMOylation
targets significantly regulated upon MMC treatment with
and without ATRi and ATMi reveals that these consist of core
ATR-activating proteins and DDR responders, showing remark-
able orchestration of this functional group (Figure S4B; Jentsch
and Psakhye, 2013).
Together, these proteomics experiments suggest that
regulation of phosphorylation and SUMOylation occurs
within overlapping networks of RS responders and that these
may be subjected to common control by the same apical DDR
kinases.Cell Reports 21, 546–558, October 10, 2017 551
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Figure 4. Proteomics Analysis of TOPBP1 SUMOylation Regulation by ATR and ATMis
(A) Schematic of kinase activities at progressive stages of RS induced byMMC treatment and in combination with ATR and ATM inhibition. The blue and red bars
represent the level of activation of the ATR and ATM kinases, respectively. The shaded backgrounds represent the increasing levels of replication stress and
damage that can be induced by MMC and ATRi co-treatment, yellow being less and red being extreme RS.
(B) Experimental design for label-free proteomics analysis of TOPBP1 SUMOylation uponMMC treatment with and without ATRi (ATR-45) and ATMi (KU55933) in
FLAG-SUMO2 U-2-OS cells.
(C) Volcano plot of all ratios of MMC- and ATR-treated cells compared with MMC alone from enriched SUMOylated proteins, using a t test to determine
significantly modulated (FDR < 0.05) targets (indicated in red).
(D) SUMOylation levels for TOPBP1, ATR, and ATRIP from the proteomics analysis and SUMO as a negative control. UT, untreated (cells that were released into
DMSO without MMC or inhibitors).
See also Figure S4 and Table S4.ATM and ATRModulate a Global SUMOylation Response
to RS
We next sought to determine whether modulation of protein
SUMOylation by ATM and ATR was a general mechanism under
other conditions of RS. Using HU, an inhibitor of dinucleotide
triphosphate (dNTP) synthesis that causes DNA replication
fork stalling, we could reproduce the pattern of TOPBP1
SUMOylation observed for MMC with and without ATRi and
ATMi co-treatment (Figure 5A). TOPBP1 SUMOylation was
increased upon 3 hr of HU treatment, further massively
enhanced by co-treatment with ATRi, and then attenuated
by addition of ATMi (Figure 5A). However, after 30 min HU552 Cell Reports 21, 546–558, October 10, 2017and ATRi treatment, only a modest increase of TOPBP1
SUMOylation was detected. This pattern is in accordance with
replication forks breaking after longer treatment with replication
stressors and checkpoint inhibition, thereby also inducing
ATM signaling (Figure 5A; Figure S5A). Furthermore, treatment
with high-dose ionizing radiation (IR), which also induces DSBs
and ATM activation, did not induce TOPBP1 SUMOylation,
indicating that this regulation is specific to RS-associated
DNA breaks (Figure 5A). We further validated this pattern of
TOPBP1 SUMOylation using two different pharmacological
inhibitors for ATM and ATR and with one CHK1 inhibitor
(CHK1i) (Figure S5A). Analogous to ATR, inhibition of CHK1, a
A
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prominent substrate and mediator of ATR checkpoint signaling,
results in replication fork breakage and ATM activation (Fig-
ure S5A). Interestingly, TOPBP1 was also hyper-SUMOylated
upon CHK1i and HU co-treatment (Figure S5A). Collectively,
these observations indicate that modulation of the SUMOylation
response to RS by these central DDR kinases could be a general
regulatory mechanism and not only specific to MMC treatment.
To elaborate on the magnitude of this mechanism, we
performed a large-scale proteomics experiment to analyze
SUMOylation and phosphorylation site regulation under these
conditions. Specifically, we enriched SUMOylated and phos-
phorylated peptides from cells treated with HU in combination
with and without CHK1i and ATMi for analysis by LC-MS/MS
(Figures S5B and S5C). CHKi was used rather than ATRi to
permit initiation of the RS response by ATR. Four biological
replicates were performed, and each sample was analyzed
twice by MS for label-free quantification (Figure S5D). We iden-
tified 3,465 SUMOylated peptides corresponding to 1,590
SUMOylation acceptor sites, of which 2,450 peptides were
quantified at least three times under at least one of the three
treatment conditions (Figure 5B; Table S5). Using ANOVA signif-
icance testing to compare the dynamics of the modifications
between treatments, 1,375 SUMOylated peptides, correspond-
ing to 816 SUMO acceptor sites, were deemed to be regulated
under at least one condition (Figure 5B). Similarly, 3,373 high-
confidence phosphorylation sites were found to be modulated,
and 127 proteins harbored changes of both PTMs (Figures 5B
and 5C). To determine whether there was interdependency be-
tween SUMOylation and phosphorylation in our dataset (for
example, with the PDSM motif; Hietakangas et al., 2006), we
analyzed our raw MS data to identify co-occurring phosphoryla-
tion sites on the enriched SUMO peptides. We identified 127
phosphorylation sites in the SUMO-enriched dataset, of which
26 were on SUMOylated peptides (Table S5). Although the over-
lap is modest, 64% of these phosphorylation sites harbored a
proline in the residue directly C-terminal to the phosphorylated
serine/threonine residue, conforming to part of the PDSM motif
(JKxExxSP) (Table S5).
We further analyzed our dataset to determine the degree
of control the DDR kinases exert on protein SUMOylation in
response to RS. It is evident from the number of significantly
perturbed SUMOylation acceptor sites that regulation of this
modification by ATM and ATR is a global mechanism in the
response to RS because more than 50% of the quantified sites
were significantly regulated (Figure 5B). We performed unsuper-
vised hierarchical clustering of the regulated phosphorylation
sites and SUMOylated peptides to determine the dynamics of(B) The number of peptides, sites, and proteins identified and quantified from the
peptides from all experimental conditions with a 1% FDR rate. Targets quantified
one condition were used for further analysis. For phosphorylation events, a localiz
SUMOylation peptides and phosphorylation sites that were modulated under an
(FDR < 0.05).
(C) Overlap of proteins with regulated SUMOylation and phosphorylation.
(D) Unsupervised hierarchical clustering of the 1,375 significantly perturbed SUM
STRING-based functional network analysis of the proteins in the clusters and d
selected proteins (pink for SUMOylation sites and blue for phosphorylation sites). T
red phospho-peptide sequences are those that confer to the ATM and ATR sequ
See also Figure S5 and Table S5.
554 Cell Reports 21, 546–558, October 10, 2017this regulation (Figure 5D; Figure S5E). For both modifications,
we identified a cluster that showed the same dependency on
CHK1 and ATM as observed for TOPBP1 by western blotting
(Figure 5D). In this cluster, protein SUMOylation and phosphory-
lation sites increased upon co-treatment of HU with CHK1i
compared with HU alone and was attenuated upon further
addition of ATMi (Figure 5D; Figure S5E). Interestingly, GO anal-
ysis revealed that these clusters were enriched in proteins
involved in DNA replication and recombination (Figure 5D;
Figure S5E). Among the SUMO-regulated proteins in this cluster
were key regulators of DNA replication and homologous recom-
bination, such as TOP2A (DNA topoisomerase 2-alpha), BLM
(Bloom syndrome protein), and BRCA1 as well as its constitutive
interactor BARD1 (Figure 5D). Moreover, the dynamics of the
modifications in these specific clusters are in accordance with
the expected and observed phosphorylation profiles of targets
of ATR and ATM (Figures 5A and 5D; Figures S5A and S5E).
Additionally, a cluster of proteins with significantly increased
SUMOylation upon HU and CHK1i co-treatment, but unchanged
by addition of ATMi was enriched in proteins involved in DDR and
DNA repair (Figure 5D). This included UIMC1, RBBP(CtIP), and,
interestingly, also topoisomerase I-binding arginine/serine-rich
protein (TOPORS), a dual ubiquitin/SUMO E3 ligase that is
known to play a role in the DDR (Lin et al., 2005; Marshall
et al., 2010). Noteworthy, a substantial fraction of SUMOylation
sites were modulated inversely, being unaffected or only slightly
modulated by CHK1 inhibition but increasing dramatically upon
co-inhibition of ATM (Figure 5D). This further indicates that
ATM is a central regulator of protein SUMOylation in the DDR
and, possibly, more specifically in protein deSUMOylation. This
subset of SUMO-regulated proteins was enriched for house-
keeping biological processes such as RNA metabolism, tran-
scription, and chromatin remodeling (Figure 5D). Our findings
demonstrate that SUMOylation is regulated globally in response
to RS by the chief DDR kinases ATM and ATR.
DISCUSSION
Context-specific and dynamic post-translational protein modifi-
cations are well-established regulators of the signaling pathways
that protect eukaryotic DNA integrity during the tremendous
task of replication. Advancements in speed, resolution, and
sensitivity of MS-based technologies have revolutionized the
study of global PTM biology (Olsen and Mann, 2013). With this
rise in global PTM data, it has become evident that efficient
cellular responses, such as those that safeguard genomic
integrity, require the precise and timely coordination of severalproteomics analysis. Shown are total phosphorylation sites and SUMOylated
at least three times from all biological and technical replicates under at least
ation probability of at least 0.75 (high confidence) was also required. Perturbed
y one condition compared with another were determined by ANOVA testing
Oylation peptides. Shown is GOBP enrichment analysis of the clusters with
ot plot representation of SUMOylation and phosphorylation site changes on
hemodified sequence is shownwith themodification site in the center, and the
ence motif, S/T-Q.
PTMs and the different enzymes that regulate them (Papouli
et al., 2005). Integrated analysis of PTMs is therefore pertinent
for our understanding of the molecular mechanisms that
respond to DNA damage and RS. Using state-of-the-art prote-
omics methodologies, we mapped nearly 1,400 regulated
SUMOylation acceptor sites and 3,300 regulated phosphoryla-
tion sites in response to the chemotherapeutic agents MMC
and HU. Our study reveals that SUMOylation is regulated by
the most dominant, apical DDR kinases ATR and ATM, which
are known to initiate and coordinate the phosphorylation re-
sponses to RS and replication fork breakage.
In accordance with previous studies, we found that RS elicits
increased SUMOylation of the core ATR-activating proteins,
including TOPBP1 and ATRIP. Interestingly, previous studies
have shown that the SUMOylation of ATR and its constitutive
interactor ATRIP is necessary for efficient ATR-dependent
checkpoint signaling (Wu and Zou, 2016; Wu et al., 2014).
Further, here we showed that TOPBP1, a key co-activator of
ATR, undergoes increased SUMOylation in response to
MMC-induced RS. This indicates that SUMOylation of this
factor, in addition to that of ATR and ATRIP, may be important
for ATR-dependent checkpoint signaling. However, further
biochemical and molecular biological analyses are required to
confirm the precise role of TOPBP1 SUMOylation in ATR activa-
tion. In addition, our data suggest that SUMOylation is a com-
mon and relevant modification of a number of proteins involved
in ATR activation in response to RS.
We aimed to uncover the interplay between phosphorylation
and SUMOylation of protein networks in the RS response. Using
an integrated proteomics approach, we found that protein
SUMOylation was widely modulated by the main regulatory
kinases that mediate the phosphorylation response. Parallel
proteomics analysis of changes in these two PTMs revealed
co-regulation of a number of central RS and DDR responders,
including BRCA1, BARD1, and TOPBP1. BRCA1 SUMOylation
and phosphorylation have individually been found to play a key
role in the function of this protein because SUMOylation has
been shown to increases its ubiquitin ligase activity (Morris
et al., 2009). It will be interesting in future analyses to determine
whether there is co-dependency or cross-regulation of these
modifications in the proteins that harbor both phosphorylation
and SUMOylation and, in particular, the relevance of this for
the functions of central DDR proteins.
Our approach, to study co-regulated SUMO- and phospho-
modified proteins, proved to be successful to identify key co-
modified targets. TOPBP1 was the most highly co-regulated
protein in our dataset upon 8 hr of MMC treatment, and we found
that TOPBP1 SUMOylation was heavily modulated by ATR
inhibition during RS and by ATM upon replication fork breakage.
We found this particularly interesting because these central DDR
kinases (particularly ATM) are well known to orchestrate various
PTM-based networks upon threats to the DNA (Smith et al.,
2010). However, the effect of the apical DDR kinases on global
protein SUMOylation in response to DNA damage and replica-
tion stress has not yet been shown. We determined that
such regulation by kinases not only applies to TOPBP1 but,
further, to over 800 nearly 1,400 SUMOylation acceptor sites in
response to HU-induced RS, demonstrating global regulationof SUMOylation by these kinases in the maintenance of genome
stability. Interestingly, we observed decreased SUMOylation of a
large subset of proteins upon ATM inhibition under conditions
that induce replication fork breakage. This suggests that ATM
may be important for global deSUMOylation to maintain and
control physiological levels of protein SUMOylation.
In our bioinformatics analysis of proteins with increased
SUMOylation upon treatment with MMC and HU, we found clus-
ters of co-regulated proteins that are known to function together
in the RS response. In addition to the ATR activation proteins,
BRCA1 and BARD1, we also found Fanconi anemia proteins
and DSB response proteins, like MDC1, NBN, and CtIP. This is
particularly interesting in light of the recent idea that SUMO
functions as a molecular glue to mediate protein complex forma-
tion under specific cellular states and that this modification takes
form of a ‘‘SUMO spray’’ (Jentsch and Psakhye, 2013). A
consequence of this hypothesis is that SUMOylation should
occur on functionally related proteins to promote cooperation
and interaction in protein networks, and this is precisely what
we observed in our dataset. Interestingly, we found that proteins
co-modified by SUMOylation and phosphorylation generally
have many regulated sites in response to RS. This poses a
challenge for functional studies because site-directed mutagen-
esis of specific SUMOylation acceptor sites has been shown to
result in little effect on overall protein SUMOylation or function
(Jentsch and Psakhye, 2013).
Here, we present an integrated analysis of global protein phos-
phorylation and SUMOylation in RS responses and the largest
resource to date of regulated SUMOylation targets under these
conditions. We propose that increased SUMOylation occurs on
specific and relevant factors in response to distinct DNA lesions,
as illustrated by the SUMOylation dynamics upon RS and
RS-induced DSBs. Our data suggest that these SUMOylation re-
sponses are orchestrated by the apical kinases ATR and ATM in
parallel with or as part of their phosphorylation signaling. These
findings, and further investigations of the co-regulation of these
two modifications, are currently of great interest because the
induction of RS-provoked DSBs is increasingly used in chemo-
therapy to induce cancer cell killing (Li and Heyer, 2008). In light
of the essential role of SUMO in the maintenance of genomic
integrity (Bergink and Jentsch, 2009; Jackson and Durocher,
2013), the increasing interest in this system as a druggable target
(Kessler et al., 2012) will require the understanding of how its
perturbation affects global signaling networks.
EXPERIMENTAL PROCEDURES
Further details and an outline of the resources used in this work can be found in
the Supplemental Experimental Procedures.
Cell Culture
Human U-2-OS osteosarcoma cells were cultured in complete DMEM. For
SILAC-based experiments, cells were SILAC-labeled as reported previously
(Hekmat et al., 2013; Olsen et al., 2006). For further details regarding cell
culture, synchronization, and drug treatments, see the Supplemental Experi-
mental Procedures.
Stable Cell Line Generation
To generate stable cell lines for SUMO enrichment, U-2-OS cells were infected
with a lentivirus encoding either FLAG-tagged SUMO-2 (FLAG-SUMO2) orCell Reports 21, 546–558, October 10, 2017 555
His10-SUMO-2-K0-Q87R (His10-S2-K0), as described previously (Hendriks
et al., 2014; Schimmel et al., 2014). Further details are provided in the Supple-
mental Experimental Procedures.
SUMO Target Protein Enrichment
Enrichment of SUMOylated proteins was performed as described previously
(Schimmel et al., 2014). Briefly, cell were harvested in lysis buffer and
sonicated prior to enrichment of SUMOylated protein using monoclonal
ANTI-FLAG M2 beads (Sigma) for 90 min at 4C with rotation. Following
washes, the bound proteins were eluted using 1 mM FLAG-M2 epitope
peptide and, thereafter, filtered through an Amicon Ultra 10 kDa nominal
molecular weight limit (10k NMWL) spin filter (Millipore). The resulting proteins
were processed by in-gel digestion for LC-MS/MS analysis. For details
regarding enrichment of SUMO target proteins and in-gel digestion, see the
Supplemental Experimental Procedures.
SUMO Peptide Enrichment
SUMOylated peptides were enriched as described previously by Hendriks
et al. (2014). Briefly, thirty 15-cm plates of U-2-OS cells per condition were
harvested in PBS, lysed in 6M guanidine-HCl lysis buffer, and sonicated.
SUMOylated proteins were enriched from equal amounts of protein for each
condition by nickel-nitrilotriacetic acid (Ni-NTA) agarose beads overnight at
4C. Proteins were eluted using 500 mM imidazole twice. The eluted proteins
were filtered and concentrated in spin filters digested with endolysylpeptidase
(LysC). SUMOylated peptides were subsequently enriched with Ni-NTA
agarose beads at 4C for 5 hr and eluted using 500 mM imidazole. The
enriched peptides were filtered and concentrated prior to digestion with
trypsin and analysis by LC-MS/MS. For detailed SUMO peptide enrichment
procedures, see the Supplemental Experimental Procedures.
MS Analysis
Peptide mixtures were analyzed using the EASY-nLC system (Proxeon,
Odense, Denmark) connected to a Q-Exactive mass spectrometer (Thermo
Fisher Scientific, Bremen, Germany) as described previously (Kelstrup et al.,
2012). Details are provided in the Supplemental Experimental Procedures.
Raw Data Processing
Raw data were analyzed using MaxQuant v1.4.1. and v1.5.11 against the
complete human UniProt database. See the Supplemental Experimental
Procedures for detailed descriptions.
Bioinformatics Analysis
All functional network analysis were done using the STRING database
(Szklarczyk et al., 2015) and further processed with Cytoscape (www.
cytoscape.org). Hierarchical clustering and ANOVA t test were performed
using Perseus. For ANOVA, the false discovery rate (FDR) threshold was set
to 0.05. Sequence motif analysis was performed using IceLogo (Colaert
et al., 2009). Details are provided in the Supplemental Experimental
Procedures.
DATA AND SOFTWARE AVAILABILITY
The accession number for the raw mass spectrometric data reported in this
study is ProteomeXchange Consortium: PXD006361.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and five tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2017.09.059.
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